Gastroesophageal reflux disease: When East meets West

• Published in: Journal of digestive diseases Vol. 23; no. 4; pp. 192 - 195
• Main Author: Xiao, Ying Lian
• Format: Journal Article
• Language: English
• Published: Melbourne Wiley Publishing Asia Pty Ltd 01.04.2022; Wiley Subscription Services, Inc
• Subjects: Clinical trials; diagnosis; Endoscopy; Esophagitis, Peptic; Fundoplication - methods; Gastroesophageal reflux; Gastroesophageal Reflux - diagnosis; Gastroesophageal Reflux - epidemiology; Gastroesophageal Reflux - etiology; gastroesophageal reflux disease; guideline; Humans; Laparoscopy; Malignancy; Proton pump inhibitors; Proton Pump Inhibitors - therapeutic use; Quality of Life; Sphincter; therapy; Treatment Outcome; United States > US; China; diagnosis; gastroesophageal reflux disease; therapy; guideline
• ISSN: 1751-2972; 1751-2980
• DOI: 10.1111/1751-2980.13090

Gastroesophageal reflux disease (GERD) is common worldwide and poses a huge challenge to health. Consensuses and guidelines on the diagnosis and management of GERD in China and the USA have recently been updated. The divergence between these guidelines indicates the differences in the conception of this disease by experts in different countries, and is influenced by available medications and interventional procedures. Prompt endoscopy has been advocated in China due to a high prevalence of upper gastrointestinal (GI) cancer, while endoscopy has been reserved for those who are at a risk of malignancy or who are reisitant to proton pump inhibitors (PPIs) in the USA. A potassium channel acid‐blocker is widely used in Asian countries and has proven efficacy. Moreover, it has been recommended, together with PPIs, as a primary therapy for GERD in China; while PPI alone is recommended as a first‐line treatment in the USA. Although more prokinetics are available in China than in the USA and can alleviate GERD symptoms when combined with PPI, the choice of prokinetics is limited in the USA, leading to completely opposite attitudes to prokinetics in the two countries. Novel anti‐reflux procedures have been introduced in both countries. Transoral incisionless fundoplication (TIF) is recommended as an endoscopic anti‐reflux procedure, and magnetic sphincter augmentation (MSA) is recognized as equivocal to conventional laparoscopic fundoplication in the USA. However, radiofrequency ablation is more popular in China, and clinical trials on TIF and MSA are not complete, which results in diverse opinions about suitable anti‐reflux procedures in China. A comparison of the guidelines may therefore shed light on the multiple dimensions of GERD and thus deepen our understanding of the disease.